{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:13:17Z","timestamp":1789017197158,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T00:00:00Z","timestamp":1205280000000},"content-version":"vor","delay-in-days":4788,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[1995,2]]},"abstract":"<jats:p><jats:bold>Summary. <\/jats:bold> We have examined the factors influencing prognosis in over 4000 children with acute lymphoblastic leukaemia (ALL) aged 1\u201314 who have been treated on consecutive MRC UKALL trials from 1972 to 1990. During this time the results of treatment have improved steadily but are consistently superior in girls when compared with boys; the 5\u2010year event\u2010free survival in girls improving from 51% to 71% and in boys from 31% to 57%. These results were independent of age and presenting leucocyte count. Boys not only had a testicular relapse rate of 10% but an excess of bone marrow relapse, particularly evident after 2 years from diagnosis. Other prognostic factors included organomegaly and the morphology of leukaemic blast cells; immuno\u2010phenotype of the leukaemia, however, had no independent significance after allowance for age, sex and leucocyte count.<\/jats:p><jats:p>The influence of sex on prognosis was reaffirmed when we examined various methods of identifying children at highest risk of treatment failure for whom alternative therapy such as bone marrow transplantation might be justified. In MRC UKALL X children had been deemed \u2018high risk\u2019 on the basis of leucocyte count alone, but with further follow\u2010up it has become apparent that girls with an initial leucocyte count of &gt; 100 \u00d7 10<jats:sup>9<\/jats:sup>\/1 have a similar prognosis to boys with a lower count. We therefore derived a risk score based on sex, age and count which has given better discrimination between standard risk (66% 5\u2010year survival) and poor risk (39%) survival than other methods. This group of worse\u2010risk children includes 16% of boys but only 3% of all girls.<\/jats:p><jats:p>Gender remains an important prognostic factor in UKALL trials and there are very few girls who are at highest risk of treatment failure. The reasons for this remain unclear, but the pattern of relapses suggests that boys more often get inadequate systemic therapy. We postulate that the reasons for treatment failure may relate to sensitivity to continuing (maintenance) chemotherapy.<\/jats:p>","DOI":"10.1111\/j.1365-2141.1995.tb03313.x","type":"journal-article","created":{"date-parts":[[2008,3,12]],"date-time":"2008-03-12T11:39:51Z","timestamp":1205321991000},"page":"364-372","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":99,"title":["Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials*"],"prefix":"10.1111","volume":"89","author":[{"given":"J. M.","family":"Chessells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. S.","family":"Lilleyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. B.","family":"Eden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,3,12]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.2.415.415"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/0268-960X(92)90015-I"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92103-M"},{"key":"e_1_2_1_5_1","first-page":"1275","article-title":"Acute lymphoblastic leukaemia in infancy: experience in MRC UKALL trials. Report from the Medical Research Council Working Party on childhood leukaemia","volume":"8","author":"Chessells J.M.","year":"1994","journal-title":"Leukemia"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2428::AID-CNCR2820671004>3.0.CO;2-J"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.1.117.117"},{"key":"e_1_2_1_8_1","first-page":"637","article-title":"Review of the incidence and clinical relevance of myeloid antigen\u2010positive acute lymphoblastic leukemia","volume":"5","author":"Drexler H.G.","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.tb07788.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04415.x"},{"key":"e_1_2_1_11_1","first-page":"58","article-title":"Children under two years treated according to the Medical Research Council UKALL VIII study and trial 1980\u20131984 (on behalf of the Medical Research Council Working Party on Leukaemia in Childhood)","volume":"18","author":"Eden O.B.","year":"1992","journal-title":"British Journal of Cancer"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.9.1570"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.11.2234"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.66.4.462"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1992.tb12081.x"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(90)91745-V"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92400-7"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/mpo.2950140317"},{"key":"e_1_2_1_19_1","first-page":"787","article-title":"Effects of varying radiation schedule, cyclosphosphamide treatment, and duration of treatment in acute lymphoblastic leukaemia","author":"Medical Research Council","year":"1978","journal-title":"British Medical Journal"},{"key":"e_1_2_1_20_1","first-page":"511","article-title":"Duration of chemotherapy in childhood ALL","volume":"10","author":"Medical Research Council","year":"1982","journal-title":"Medical and Pediatric Oncology"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.12.1758"},{"key":"e_1_2_1_22_1","first-page":"408","article-title":"Improvement in treatment for children with acute lymphoblastic leukaemia","author":"Medical Research Council","year":"1986","journal-title":"Lancet"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.201"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a057856"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.2.343.343"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V76.8.1449.1449"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.8.1341"},{"key":"e_1_2_1_30_1","first-page":"150","article-title":"Impact of three methods of treatment intensification on acute lymphoblastic leukemia in children: long\u2010term results of St Jude Total Therapy Study X","volume":"6","author":"Pui C.\u2010H.","year":"1992","journal-title":"Leukemia"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90733-6"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1991.9.12.2183"},{"key":"e_1_2_1_33_1","first-page":"741","article-title":"Differences in prognosis for boys and girls with acute lympho\u2010blastic leukaemia","author":"Sather H.","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb07713.x"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.4.606"},{"key":"e_1_2_1_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.3.527"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.1995.tb03313.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.1995.tb03313.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.1995.tb03313.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T02:59:17Z","timestamp":1698289157000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.1995.tb03313.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1995,2]]}},"alternative-id":["10.1111\/j.1365-2141.1995.tb03313.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.1995.tb03313.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,2]]},"assertion":[{"value":"2008-03-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}